An efficient deep learning-based strategy to screen inhibitors for GluN1/GluN3A receptor.

IF 6.9 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Ze-Chen Wang, Yue Zeng, Jin-Yuan Sun, Xue-Qin Chen, Hao-Chen Wu, Yang-Yang Li, Yu-Guang Mu, Liang-Zhen Zheng, Zhao-Bing Gao, Wei-Feng Li
{"title":"An efficient deep learning-based strategy to screen inhibitors for GluN1/GluN3A receptor.","authors":"Ze-Chen Wang, Yue Zeng, Jin-Yuan Sun, Xue-Qin Chen, Hao-Chen Wu, Yang-Yang Li, Yu-Guang Mu, Liang-Zhen Zheng, Zhao-Bing Gao, Wei-Feng Li","doi":"10.1038/s41401-025-01513-x","DOIUrl":null,"url":null,"abstract":"<p><p>The GluN1/GluN3A receptor, a unique excitatory glycine receptor recently identified in the central nervous system, challenges traditional perspectives of N-methyl-D-aspartate (NMDA) receptor diversity and glycinergic signaling. Its role in emotional regulation positions it as a potential therapeutic target for neuropsychiatric disorders. However, pharmacological research on GluN1/GluN3A receptors remains at an early stage. Traditional high-throughput screening methods for ion channel drug discovery often lack efficiency, particularly when applied to large compound libraries. To address this concern, we designed a deep learning-based strategy that balances efficiency and accuracy for identifying GluN1/GluN3A inhibitors. First, a sequence-based scoring function was developed to rapidly screen a library containing 18 million compounds, reducing the pool to approximately 10<sup>5</sup> candidates. Next, two complex-based scoring functions, IGModel and RTMScore, were employed to precisely score and rank the remaining candidates. Finally, an active molecule with an IC<sub>50</sub> of 2.87 ± 0.80 μM for the GluN1/GluN3A receptor was confirmed through whole-cell voltage-clamp electrophysiology. This study also presents a paradigm for integrating deep learning into rapid and precise high-throughput screening.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":" ","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-025-01513-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

The GluN1/GluN3A receptor, a unique excitatory glycine receptor recently identified in the central nervous system, challenges traditional perspectives of N-methyl-D-aspartate (NMDA) receptor diversity and glycinergic signaling. Its role in emotional regulation positions it as a potential therapeutic target for neuropsychiatric disorders. However, pharmacological research on GluN1/GluN3A receptors remains at an early stage. Traditional high-throughput screening methods for ion channel drug discovery often lack efficiency, particularly when applied to large compound libraries. To address this concern, we designed a deep learning-based strategy that balances efficiency and accuracy for identifying GluN1/GluN3A inhibitors. First, a sequence-based scoring function was developed to rapidly screen a library containing 18 million compounds, reducing the pool to approximately 105 candidates. Next, two complex-based scoring functions, IGModel and RTMScore, were employed to precisely score and rank the remaining candidates. Finally, an active molecule with an IC50 of 2.87 ± 0.80 μM for the GluN1/GluN3A receptor was confirmed through whole-cell voltage-clamp electrophysiology. This study also presents a paradigm for integrating deep learning into rapid and precise high-throughput screening.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmacologica Sinica
Acta Pharmacologica Sinica 医学-化学综合
CiteScore
15.10
自引率
2.40%
发文量
4365
审稿时长
2 months
期刊介绍: APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信